Rubia cordifolia

Rubia cordifolia is an Ayurvedic herb containing anthraquinones and rubimaillin that demonstrates anti-inflammatory and neuroprotective properties. Its primary mechanism involves modulating cytokine production and enhancing antioxidant enzyme activity.

Origin & History

Rubia cordifolia is a perennial climbing vine from the Rubiaceae family whose rhizome (underground stem) serves as the primary medicinal component in traditional Asian medicine systems. Medicinal preparations are typically derived from aqueous or methanol extracts of the roots and aerial parts, which contain quinone derivatives and other bioactive compounds.

Historical & Cultural Context

R. cordifolia has a long history in traditional Chinese medicine, where the rhizome is used for improving blood circulation, hemostasis (blood clotting control), and activation of collateral circulation. The plant is also used in broader Asian traditional medicine systems.

Health Benefits

• Anti-inflammatory effects: Animal studies show reduced IL-1β and TNF-α cytokines in inflammatory bowel disease models (preclinical evidence only)
• Neuroprotective potential: Phytosomal formulations increased antioxidant enzymes (SOD, catalase) and reduced oxidative markers in rat sciatic nerve tissue (preclinical evidence only)
• Ulcerative colitis support: Mollugin component at 20-40 mg/kg reduced inflammatory markers in mice with DSS-induced colitis (preclinical evidence only)
• Rheumatoid arthritis management: Extract showed histological improvements in articular cartilage in rat models (preclinical evidence only)
• Diabetic neuropathy protection: Root extract demonstrated neuroprotective effects in Wistar rat models (preclinical evidence only)

How It Works

Rubia cordifolia's anthraquinone compounds, particularly rubimaillin and purpurin, inhibit pro-inflammatory cytokine production including IL-1β and TNF-α. The herb upregulates endogenous antioxidant enzymes like superoxide dismutase (SOD) and catalase while reducing lipid peroxidation markers. These mechanisms contribute to its anti-inflammatory effects and potential neuroprotective activity.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for R. cordifolia. All available evidence comes from preclinical animal studies in rats and mice, with researchers explicitly noting that 'clinical safety data for R. cordifolia is lacking' and 'most studies are preclinical.'

Clinical Summary

Current evidence for Rubia cordifolia is primarily preclinical, with animal studies showing reduced inflammatory markers in IBD models. Phytosomal formulations demonstrated increased SOD and catalase activity in rat sciatic nerve tissue studies. No human clinical trials have been published to date establishing therapeutic efficacy or optimal dosing. The existing research, while promising, requires human validation studies.

Nutritional Profile

Rubia cordifolia (Indian Madder) is a medicinal root herb, not typically consumed as a food source, so conventional macronutrient profiling is limited. Key documented constituents include: ANTHRAQUINONES (primary bioactives) — Purpurin (0.1–0.3% dry weight), Munjistin, Pseudopurpurin, Xanthopurpurin, and Rubiadin are the dominant pigment compounds; NAPHTHOHYDROQUINONES — Mollugin is present at measurable concentrations in root extracts, active in studies at 20–40 mg/kg range (preclinical); TANNINS — Rubiprasin A, B, C and garancin-type tannins contribute astringent properties; TRITERPENOIDS — Oleanolic acid and related saponins present in root bark fractions; IRIDOIDS — Asperuloside and related glycosides detected in aerial parts; POLYPHENOLS — General phenolic content estimated at 15–25 mg GAE/g dry root extract in published assays; MINERALS (trace, from root material) — Iron, calcium, and potassium detected at low concentrations, not nutritionally significant at typical medicinal doses; FIBER — Root material contains structural cellulose/lignin but bioavailable dietary fiber is negligible in extract form; PROTEIN — Less than 5% by dry weight in crude root powder; BIOAVAILABILITY NOTE — Anthraquinone glycosides require gut microbiota hydrolysis for aglycone activation; phytosomal formulations (phosphatidylcholine complexes) have demonstrated enhanced absorption of lipophilic constituents like mollugin in preclinical models; standardized extracts are typically normalized to purpurin or anthraquinone content (1–5%).

Preparation & Dosage

Animal study dosages only: Aqueous extract 250-1,000 mg/kg body weight (oral), with 500 mg/kg showing efficacy in colitis models; Mollugin 10-40 mg/kg body weight; No standardized human dosing recommendations exist. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other anti-inflammatory herbs, antioxidants, neuroprotective compounds, traditional Ayurvedic herbs, adaptogenic plants

Safety & Interactions

Rubia cordifolia safety data in humans is limited due to lack of clinical trials. Traditional use suggests general tolerability, but potential side effects remain undocumented. The herb may theoretically interact with anticoagulant medications due to anthraquinone content. Pregnancy and lactation safety has not been established, so use should be avoided during these periods.